Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Mar;4(3):283-90.
doi: 10.2217/imt.12.3.

Cellular immunotherapy for soft tissue sarcomas

Steven Eric Finkelstein  1 , Mayer Fishman, Anthony P Conley, Dmitry Gabrilovich, Scott Antonia, Alberto Chiappori
Affiliations
Review

Cellular immunotherapy for soft tissue sarcomas

Steven Eric Finkelstein et al. Immunotherapy. 2012 Mar.

Abstract

Soft tissue sarcomas are rare neoplasms, with approximately 9000 new cases in the USA every year. Unfortunately, during the past two decades, there has been little progress in the treatment of metastatic soft tissue sarcomas beyond the standard approaches of surgery, chemotherapy and radiation. Immunotherapy is a modality complementary to conventional therapy. It is appealing because functional antitumor activity could affect both local-regional and systemic disease, and act over a prolonged period of time. In this report, we review immunotherapeutic investigative strategies that are being developed, including several tumor vaccine, antigen vaccine and dendritic cell vaccine strategies.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement: none of the authors have a conflict of interest.

Figures

Figure 1
Figure 1. MCC 14497 Trial Design
General treatment scheme for cellular dendritic cell (DC) immunotherapy of sarcoma.
See this image and copyright information in PMC

References

    1. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998;21(3):317–321. - PubMed
    1. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917–924. TCR-based gene therapies directed against NY-ESO-1 may represent a new and effective therapeutic approach for patients with melanoma and synovial cell sarcoma. - PMC - PubMed
    1. Gabrilovich DI. Dendritic cell vaccines for cancer treatment. Curr Opin Mol Ther. 2002;4(5):452–458. - PubMed
    1. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188(7):1359–1368. - PMC - PubMed
    1. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392(6671):86–89. Human dendritic cells, efficiently present antigens derived from apoptotic cells, stimulating class I-restricted CD8+ CTLs and suggesting a mechanism by which potent APCs acquire tumor antigens for stimulation or tolerization of CTLs. - PubMed

MeSH terms